Friday, 06 Dec 2019

You are here

MRI in the Diagnosis and Management of Polymyalgia Rheumatica

Polymyalgia rheumatica (PMR) is a common condition seen by both primary care and in the rheumatology office.

Many cases of PMR are extremely straightforward for a trained rheumatologist — with easy to recognize joint pain and stiffness in the shoulder and hip girdles, elevated inflammatory markers, and a rapid response to moderate doses of prednisone (15-20mg).

This said, as rheumatologists we tend to see many of the more difficult cases of PMR.

PMR continues to primarily be a clinical diagnosis, without any specific testing that is typically done to confirm the condition. Despite numerous advances in medication therapy for other rheumatologic diseases, the mainstay of PMR treatment continues to be corticosteroids, with data supporting the use of methotrexate only coming up in the past few years.

At #ACR19, abstract 1161 looked at Gadolinium-enhanced shoulder MRI findings in patients with PMR, finding that these patients had evidence of shoulder capsulitis, rotator cuff tendonitis and focal osteitis, which was relatively specific to PMR. Additionally, they found that "rotator cuff tendonitis and synovial hypertrophy on MRI were associated with recurrences of PMR.”

As a clinician who frequently manages PMR, we occasionally do have cases where the patient doesn’t have a “classic” presentation for PMR, so it appears that Gadolinium-enhanced shoulder MRI could be useful in diagnosis for these patients.

Additionally, I occasionally find it difficult to differentiate whether a patient is having a flare or recurrence of their PMR symptoms with tapering of prednisone, versus recurrence of their osteoarthritis symptoms unmasked by tapering of steroids. Additionally, steroid withdrawal symptoms can sometimes mimic flare or recurrence of PMR.

Since PMR continues to be managed primarily with corticosteroids, accurately diagnosing a patient’s source of symptoms is the best way to minimize risk of steroid-related side effects. 


Rheumatologists' Comments

With the issues with Gadolinium and toxicity not sure I like this idea
Not surprisingly (because we do so much MSKUS), we prefer US in this context because of 1) the ability to apply color Doppler for detection of hyperemia, 2) the ability to detect synovial proliferation, 3) the ability to detect confounding conditions (tendinopathy/calcium deposition/OA), 4) the logistical convenience of the technique and rapidity of results, and 5) lower cost/no GAD exposure

More Like This

Smoking Cessation Lowers RA Disease Activity and CV Risks

A multinational cross-sectional cohort study suggests that smoking cessation in rheumatoid arthritis (RA) patients is associated with lower disease activity measures, improved lipid profiles and lower rates of cardiovascular (CV) events.

Apremilast Reduces Oral Ulcers in Behcet's Syndrome

A multinational trial finds a statistically significant number of patients with Behçet's syndrome showed a greater reduction in the number of oral ulcers with apremilast compared with placebo.

Systemic JIA-Associated Lung Disease

A disease you’ve never heard of is becoming increasingly common and carries a very poor prognosis. 

For me, one of most important aspects of attending the ACR Annual Meeting is to learn about conditions that I don’t know and that may afflict my patients when I return back home. This year’s meeting was no different.

Tapering Of Therapy In RA: Maybe Not So Aggressive Next Time

This ACR has seen some more great work on tapering of therapy in rheumatoid arthritis. It’s a hot topic and one which I get asked about all the time by my patients. Commonly when I start oral csDMARDs patients want to know how long they be will on therapy and that naturally leads to a discussion about what the plan will be in the future about tapering.

ACR 2019 - Report From Day 3 (Tuesday)

Here's my summary of key studies presented Tuesday. 

Tofacitinib in Polyarticular JIA